23andMe's Fall from $6B to Penny Stock 📉
DNA-testing firm 23andMe, once valued at $6B, faced decline due to strategic and market challenges, as detailed by WSJ.
The Wall Street Journal
1.8M views • Feb 8, 2024
About this video
DNA-testing company 23AndMe and its founder, Anne Wojcicki, aimed to revolutionize healthcare, bringing genetic tests to homes with just a tube of spit. But challenges with its business model and continued data privacy concerns for consumers have brought the company once valued at $6 billion to a valuation of nearly $0, with Nasdaq threatening to delist it.
WSJ explains what went wrong with Wojcicki’s biotech business.
Chapters:
0:00 Home DNA testing
0:49 The rise of 23andMe
2:18 The turning point
4:03 23andMe’s fall
5:23 What’s next?
What Went Wrong explores the challenging conditions and decisions that led to a company's downturn.
#23andMe #DNA #WSJ
WSJ explains what went wrong with Wojcicki’s biotech business.
Chapters:
0:00 Home DNA testing
0:49 The rise of 23andMe
2:18 The turning point
4:03 23andMe’s fall
5:23 What’s next?
What Went Wrong explores the challenging conditions and decisions that led to a company's downturn.
#23andMe #DNA #WSJ
Tags and Topics
Browse our collection to discover more content in these categories.
Video Information
Views
1.8M
Likes
18.5K
Duration
5:58
Published
Feb 8, 2024
User Reviews
4.5
(360) Related Trending Topics
LIVE TRENDSRelated trending topics. Click any trend to explore more videos.
No specific trending topics match this video yet.
Explore All Trends